Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2008-03-28Clinical Trial Update: Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis [Phase 2]
A Phase 2 trial evaluating the safety and efficacy of adalimumab in moderately to severely active psoriatic arthritis has completed. The stu…
-
CLINICAL_TRIALS research · 2008-03-05Clinical Trial Update: Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions
NIAMS-sponsored clinical trial update reports completed genetic and immune studies investigating rheumatoid arthritis, psoriatic arthritis, …
-
CLINICAL_TRIALS trial_result · 2008-03-04Clinical Trial Update: A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis [Phase 2]
A Phase 2 clinical trial evaluating intermittent fludarabine for psoriatic arthritis has completed.
-
CLINICAL_TRIALS trial_result · 2008-03-04Clinical Trial Update: Study of Psoriatic Arthritis
NIAMS-sponsored clinical trial evaluating psoriatic arthritis and psoriasis has completed.
-
EMA withdrawal · 2008-02-14EMA Withdrawn: Trudexa (adalimumab) — Abbott Laboratories Ltd.
EMA has withdrawn Trudexa (adalimumab) from the market.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2007-08-29Clinical Trial Update: Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) [Phase 3]
Phase 3 safety and efficacy results for Adalimumab in active psoriatic arthritis have been reported; the study has completed.
-
CLINICAL_TRIALS trial_result · 2007-08-29Clinical Trial Update: Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis [Phase 3]
A Phase 3 trial evaluating the safety and efficacy of adalimumab in patients with moderate to severely active psoriatic arthritis has comple…
-
CLINICAL_TRIALS research · 2007-08-16Clinical Trial Update: Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
A clinical trial investigates whether inflammatory bowel disease–associated antibodies (ASCA, ALCA, ACCA, AMCA) are present in the blood of …
-
FDA approval · 2007-07-30FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
The FDA approved a supplemental application for Humira (adalimumab) submitted by Cordavis Limited.
-
FDA approval · 2007-06-12FDA Approved: INFLIXIMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for infliximab (Remicade) submitted by Janssen Biotech, Inc. The approval updates the labeling to re…
-
FDA approval · 2007-04-30FDA Approved: METHOTREXATE — Original Application (Accord Healthcare, Inc.)
The FDA approved Accord Healthcare's original application for Methotrexate (generic).
-
FDA approval · 2007-04-19FDA Approved: INFLIXIMAB — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for infliximab (Remicade) from Janssen Biotech, Inc., updating the product labeling per the supp…
-
CLINICAL_TRIALS trial_result · 2007-04-10Clinical Trial Update: TNFalfa Blocking Treatment of Spondylarthropathies [Phase 4]
Phase 4 clinical trial evaluating TNF-alpha blockade for spondyloarthropathies has completed, including ankylosing spondylitis and psoriatic…
-
CLINICAL_TRIALS trial_result · 2007-03-23Clinical Trial Update: Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment
A clinical trial update from National Taiwan University Hospital reports differential clinical and serologic responses in psoriasis and psor…
-
FDA approval · 2007-03-13FDA Approved: ORENCIA — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA approved a supplemental application for ORENCIA (abatacept) from E.R. Squibb & Sons, L.L.C.
-
FDA approval · 2006-12-12FDA Approved: ORENCIA — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA approved a supplemental application for ORENCIA (abatacept) submitted by E.R. Squibb & Sons, L.L.C., indicating an approved update to th…
-
FDA approval · 2006-12-08FDA Approved: INFLIXIMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for infliximab submitted by Janssen Biotech, Inc.
-
FDA approval · 2006-09-26FDA Approved: INFLIXIMAB — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for infliximab from Janssen Biotech, Inc., updating the drug's labeling.
-
FDA approval · 2006-07-28FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
FDA approved a supplemental application for Humira (adalimumab) submitted by Cordavis Limited, likely to authorize a new contract manufactur…